- Companies
- Weiyuan Synthetic Biotechnology
Weiyuan Synthetic Biotechnology Funding, Investors & Competitors
Weiyuan Synthetic Biotechnology has raised $319M across 5 funding rounds, most recently a $220M undisclosed-stage round in May 2026.
Last Weiyuan Synthetic Biotechnology funding round
$220M
Undisclosed stage · May 2026
Cumulative funding Weiyuan Synthetic Biotechnology raised
$319M
across 5 funding rounds
Key investors in Weiyuan Synthetic Biotechnology
Shunxi Fund
Beijing Medical and Health Industry Investment Fund
Henan CICC Huirong Fund Management
Tan Ruiqing
Matrix Partners China
Shenzhen Capital Group
SDIC Venture Capital
CCB Investments
Weiyuan Synthetic Biotechnology Overview
About Weiyuan Synthetic Biotechnology
Weiyuan Synthetic Biotechnology, founded in December 2021, develops synthetic biology solutions for the low-carbon, low-cost production of active pharmaceutical ingredients, high value-added natural products, and platform compounds. The company uses multi-carbon-source fermentation technology to replace glucose with cheaper carbon sources, addressing cost and food-security challenges in industrial biomanufacturing. It also provides contract development and manufacturing (CDMO) services, producing APIs, small molecules, and peptides for biopharma clients.
Founded
2021
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Weiyuan Synthetic Biotechnology Funding History
Weiyuan Synthetic Biotechnology has raised a total of $319M across 5 funding rounds.
Weiyuan Synthetic Biotechnology's first fundraising round was a $14M seed round in July 2023. The most recent completed round was a $220M undisclosed-stage round in May 2026.
Weiyuan Synthetic Biotechnology funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| May 2026 | Undisclosed stage | Tan Ruiqing; Zhang Qibin; Xingyin Investment | $220M | WeiYuan Synthetic Biology (Weiyuan Synthetic Biotechnology) raised RMB 1.5 billion in a Series B financing round led by Zhang Qibin and Tan Ruiqing. The transaction was structured as an equity financing round for the synthetic biomanufacturing company, with the reported raise amount equivalent to about USD 214 million. The round provides growth capital for the company’s development and scale-up in synthetic bio-manufacturing. WeiYuan Synthetic Biology operates in synthetic biology and synthetic biomanufacturing, positioning itself in a sector focused on industrial-scale biological production. The company’s May 2026 financing adds to the capital entering China’s biotech and healthcare startup market, and the round is framed as a significant Series B for the business. |
| Mar 2026 | Series A | Henan Investment Group Huirong Fund Management; Tan Ruiqing | - | - |
| Jan 2026 | Undisclosed stage | Zhongguancun Youth Technology Venture Capital; Beijing New Materials Industry Investment Fund; CCB Investments; Beijing Medical and Health Industry Investment Fund | $43M | - |
| Aug 2024 | Series A | SDIC Venture Capital (lead); Hebei Industrial Investment; Jing Guorui; Shenzhen Capital Group; Shenzhen Venture Capital; Shunxi Fund; Henan CICC Huirong Fund Management; Beijing Medical and Health Industry Investment Fund | $42M | Weiyuan Synthetic Biotechnology (微元合成生物技术), founded in December 2021, develops synthetic biology solutions for low-carbon, energy-saving production of compounds, including APIs, high value-added natural products, and platform compounds. The company leverages multi-carbon source utilization technology, replacing glucose with cheaper carbon sources to address cost and food security issues in biomanufacturing. It has designed pipelines for low-cost biomanufacturing of bulk materials to support scale-up and commercialization. Competitors include Bota Biotech, Bluepha, Synceres, and Abiochem. In May 2022, Weiyuan completed an angel round of nearly CNY 100 million led by Matrix Partner China, with participation from BioTrack Capital, Henan Investment Group Huirong Fund, K2VC, and Hoshi Capital. Funds were allocated to R&D labs, technology enhancement, and product pipeline development. |
| Jul 2023 | Seed | Shunxi Fund (lead); Matrix Partners China; Beidaihe New District High-tech Industry Fund; Henan CICC Huirong Fund Management | $14M | Weiyuan Synthetic Biotechnology, also referred to as Weiyuan Synthesis, is a CDMO focused on manufacturing API products for the biopharma sector, providing healthcare solutions, biopharma outsourcing, small molecules, peptides, and API production with client-centric approaches emphasizing high-quality outcomes, innovation, and sustainable practices. The company, headquartered in Beijing, China, operates in the healthcare sector. It raised a total of $13.85M across 2 strategic funding rounds, with the most recent being a Seed round of $13.85M in July 2023 led by Guoguan Shunxi Fund and involving 7 other investors including Henan Investment Group. |
Who has invested in Weiyuan Synthetic Biotechnology?
17 investors have backed Weiyuan Synthetic Biotechnology across its funding rounds, including Shunxi Fund, Beijing Medical and Health Industry Investment Fund, Henan CICC Huirong Fund Management, Tan Ruiqing, Matrix Partners China and Shenzhen Capital Group.
Lead investors include SDIC Venture Capital and Shunxi Fund.
Weiyuan Synthetic Biotechnology Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| -- | 2 | Participant | Mar 2026 | |
| 2 | Lead | Jul 2023 | ||
| 2 | Participant | Jul 2023 | ||
| 2 | Participant | Aug 2024 | ||
| 1 | Participant | Jul 2023 | ||
| 1 | Participant | Jan 2026 | ||
| 1 | Participant | Aug 2024 | ||
| 1 | Participant | Mar 2026 | ||
| 1 | Participant | Aug 2024 | ||
| 1 | Participant | Jan 2026 | ||
| -- | 1 | Participant | May 2026 | |
| 1 | Participant | Jul 2023 | ||
| 1 | Participant | Aug 2024 | ||
This data is available for Pro users. Sign up to see all 17 Weiyuan Synthetic Biotechnology investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialWeiyuan Synthetic Biotechnology Competitors
Weiyuan Synthetic Biotechnology competitors include listed companies like CF Industries, Qinghai Salt Lake Industry, Industries Qatar and SABIC Agri-Nutrient, and private ones like Biobest and Agriprotein.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $7.1B | $3.2B | $20B | 3.1x | ||
| Publicly listed | $2.3B | $1.2B | $20B | 4.5x | ||
| Publicly listed | $4.4B | $1.6B | $17B | 4.4x | ||
| Publicly listed | $3.5B | $1.4B | $16B | 4.1x | ||
| Private | - | - | $1.5B | - | ||
| Private | - | - | $117M | - |
Weiyuan Synthetic Biotechnology Public Comps
Weiyuan Synthetic Biotechnology is still privately-owned, but its public comps include Corteva, BASF, Archer-Daniels-Midland, Nutrien, Muyuan Foods, Novonesis, Bunge, CF Industries, Qinghai Salt Lake Industry and Wilmar International.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $17B | $2.9B | 3.3x | 3.2x | 19.5x | 13.9x | |||
| $69B | $8.2B | 1.1x | 1.0x | 8.9x | 8.6x | |||
| $80B | $2.9B | 0.6x | 0.6x | 17.4x | 11.2x | |||
| $27B | $6.1B | 1.9x | 1.8x | 8.2x | 8.0x | |||
| $21B | $5B | 2.0x | 2.3x | 8.7x | 16.1x | |||
| $4.8B | $1.6B | 7.1x | 6.7x | 21.7x | 17.9x | |||
| $70B | $2.3B | 0.6x | 0.5x | 17.9x | 11.2x | |||
| $7.1B | $3.2B | 3.5x | 3.1x | 7.7x | 6.8x | |||
This data is available for Pro users. Sign up to see all Weiyuan Synthetic Biotechnology competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Weiyuan Synthetic Biotechnology
| When was Weiyuan Synthetic Biotechnology founded? | Weiyuan Synthetic Biotechnology was founded in 2021. |
| Where is Weiyuan Synthetic Biotechnology headquartered? | Weiyuan Synthetic Biotechnology is headquartered in China. |
| Is Weiyuan Synthetic Biotechnology publicly listed? | No, Weiyuan Synthetic Biotechnology is a private, VC-backed company. |
| How much funding has Weiyuan Synthetic Biotechnology raised? | Weiyuan Synthetic Biotechnology has raised $319M across 5 funding rounds. |
| What was Weiyuan Synthetic Biotechnology's last funding round? | Weiyuan Synthetic Biotechnology's last funding round was a $220M undisclosed-stage round in May 2026. |
| Who are Weiyuan Synthetic Biotechnology's investors? | Weiyuan Synthetic Biotechnology's investors include Tan Ruiqing, Shunxi Fund, Henan CICC Huirong Fund Management, Beijing Medical and Health Industry Investment Fund, Matrix Partners China, Zhongguancun Youth Technology Venture Capital, Hebei Industrial Investment, Henan Investment Group Huirong Fund Management, Jing Guorui, Beijing New Materials Industry Investment Fund and 7 others. |
| Which companies are comparable to Weiyuan Synthetic Biotechnology? | Companies comparable to Weiyuan Synthetic Biotechnology include CF Industries, Qinghai Salt Lake Industry, Industries Qatar, SABIC Agri-Nutrient, Biobest and Agriprotein. |
See companies similar to Weiyuan Synthetic Biotechnology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




